论文部分内容阅读
2007年宣布的艾滋病疫苗的分步试验(STEP试验)中期分析显示,基于复制缺陷性5型腺病毒载体的重组艾滋病疫苗,不仅不能保护人体免受艾滋病病毒(HIV)感染或降低HIV感染者的病毒载量,还可增加部分受试者对HIV感染的易感性。此结果使国际艾滋病疫苗研究面临着空前挑战。该文回顾了STEP试验及其对国际艾滋病疫苗研究策略的影响。
Interim analysis of the step-by-step AIDS vaccine (STEP trial) announced in 2007 showed that recombinant HIV vaccines based on replication-defective adenovirus type 5 not only failed to protect humans from HIV infection or reduce HIV infection The viral load can also increase the susceptibility of some subjects to HIV infection. This result puts the international AIDS vaccine research at an unprecedented challenge. This article reviews the STEP trial and its impact on international AIDS vaccine research strategies.